Dystrophin (DMD) - Drugs In Development, 2021

June 2021 | 161 pages | ID: DD632F4083CCEN
Global Markets Direct

Abstracts

Dystrophin (DMD) - Drugs In Development, 2021

SUMMARY

According to the recently published report 'Dystrophin - Drugs In Development, 2021'; Dystrophin (DMD) pipeline Target constitutes close to 57 molecules. Out of which approximately 51 molecules are developed by companies and remaining by the universities/institutes.

Dystrophin (DMD) - Dystrophin is a cytoplasmic protein. It anchors the extracellular matrix to the cytoskeleton via F-actin. It acts as ligand for dystroglycan. It acts as component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma.

The report 'Dystrophin - Drugs In Development, 2021' outlays comprehensive information on the Dystrophin (DMD) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Dystrophin (DMD) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 6, 1, 31 and 9 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 5 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Musculoskeletal Disorders which include indications Duchenne Muscular Dystrophy, Alport Syndrome and Muscular Dystrophy.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Dystrophin (DMD)
• The report reviews Dystrophin (DMD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Dystrophin (DMD) targeted therapeutics and enlists all their major and minor projects
• The report assesses Dystrophin (DMD) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Dystrophin (DMD) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Dystrophin (DMD)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Dystrophin (DMD) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Dystrophin (DMD) - Overview
Dystrophin (DMD) - Therapeutics Development
Dystrophin (DMD) - Therapeutics Assessment
Dystrophin (DMD) - Companies Involved in Therapeutics Development
Dystrophin (DMD) - Drug Profiles
Dystrophin (DMD) - Dormant Products
Dystrophin (DMD) - Discontinued Products
Dystrophin (DMD) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Alpha Anomeric, 2021
Pipeline by Astellas Gene Therapies, 2021
Pipeline by Code Biotherapeutics Inc, 2021
Pipeline by Daiichi Sankyo Co Ltd, 2021
Pipeline by Dystrogen Therapeutics SA, 2021
Pipeline by Editas Medicine Inc, 2021
Pipeline by Evox Therapeutics Ltd, 2021
Pipeline by FibroGenesis LLC, 2021
Pipeline by MyoGene Bio LLC, 2021
Pipeline by Myosana Therapeutics Inc, 2021
Pipeline by Nippon Shinyaku Co Ltd, 2021
Pipeline by OliPass Corporation, 2021
Pipeline by Pepgen Ltd, 2021
Pipeline by Vertex Pharmaceuticals Inc, 2021
Pipeline by Wave Life Sciences Ltd, 2021
Dormant Projects, 2021
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021